1778-74-1

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[3,2-c]pyridine-3-ethanamine is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds due to its versatile reactivity. Its potential biological and pharmacological activities include its use as an antitumor agent, an antidepressant, and an antiviral agent, making it valuable in the development of new therapeutic agents.
Used in Materials Science:
1H-Pyrrolo[3,2-c]pyridine-3-ethanamine serves as a building block for the synthesis of complex molecules and polymers in materials science. Its unique fused ring system and reactivity contribute to the creation of novel materials with specific properties for various applications.
Used in Organic Chemistry:
In the field of organic chemistry, 1H-Pyrrolo[3,2-c]pyridine-3-ethanamine is utilized as a versatile starting material for the synthesis of a wide range of organic compounds. Its ability to participate in various chemical reactions allows for the development of new molecules with potential applications in various industries.

InChI:InChI=1/C9H11N3/c10-3-1-7-5-12-9-2-4-11-6-8(7)9/h2,4-6,12H,1,3,10H2

Upstream product

• 183208-19-7 N-<2-<2-trimethylsilyl-1H-pyrrolo<3,2-c>pyridin-3-yl>ethyl>acetamide 
• 1336-21-6 ammonium hydroxide 
• 39676-14-7 2-(1H-pyrrolo[3,2-c]pyridin-3-yl)acetonitrile 
• 271-34-1 5-azaindole 
• 1378780-41-6 2-oxo-2-(1H-pyrrolo[3,2-c]pyridin-3-yl)-acetamide 
• 88511-27-7 3-iodopyridin-4-amine 

Downstream Products

• 1312891-88-5 (E)-3-(4-{[2-(1H-pyrrolo[3,2-c]pyridin-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester 
• 1312891-50-1 (E)-N-hydroxy-3-(4-{[2-(1H-pyrrolo[3,2-c]pyridin-3-yl)ethylamino]methyl}phenyl)acrylamide 

Relevant academic research and scientific papers

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.

5-Azatryptamine analogs as h5-HT6 serotonin receptor ligands

5-Aza analogs were prepared of several tryptamine derivatives and a skatole derivative known to bind at human 5-HT6 receptors and evaluated to determine if they bind in a manner similar to their indolic analogs. In general, the azatryptamines d

Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.